UNSPSC 51382801: Clofexamide

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H21ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 071P4J77HF, chemically known as acetamide, 2-(p-chlorophenoxy)-n-(2-(diethylamino)ethyl)- but generally known as clofexamide, which bears US NIH Compound Identifier 28554. European Medicines Agency schedules Clofexamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06704MIG. The term CLOFEXAMIDE is an International Non-Proprietary Name.

UNSPSC 51382801 Clofexamide (Commodity) shows minimal recent activity directly aligned with the code's nominal pharmaceutical scope. The three most recent state and local opportunities posted under or near this code—Seminole County's naloxone and drug deactivation systems procurement, Texas HHS's therapeutic pharmacy direct-to-manufacturer RFI, and the Minnesota Multistate Cooperative Purchasing Alliance's (MMCAP's) generic multi-source pharmaceuticals RFP—involve naloxone, direct pharmacy contracting, and broad OTC and generic drug supply, respectively, rather than clofexamide specifically. The MMCAP opportunity is the only true fit: it solicits manufacturers of generic pharmaceuticals to supply through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) to state and local government facilities across multiple jurisdictions, with contracts effective July 1, 2026. The other two opportunities, while pharmaceutical-adjacent, address harm reduction supplies and pharmacy benefit program restructuring, not the antibiotic scope clofexamide occupies. Issuing bodies in the recent record include county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (MMCAP, administered by the Minnesota Department of Administration).

Geographic activity centers on Florida, Texas, and the MMCAP member states (Minnesota and Oregon explicitly named). The Seminole County IFB (IFB60459723LAS) closed July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida. The MMCAP RFP (S1070000015802) issued January 20, 2026, with a proposals due date of March 26, 2026, and requires vendors to provide comprehensive National Drug Code, SKU, and pricing data for generic pharmaceuticals and OTC products, with 3 percent administrative fees and performance penalties of $200 to $1,500 per violation. The Texas RFI (HHS0017013) posted April 3, 2026, functions as exploratory market research rather than a competitive solicitation, gathering vendor capabilities for direct manufacturer-to-state pharmacy relationships. No specific budget values are disclosed across the three opportunities. The code shows limited, scattered recent procurement activity; firms pursuing opportunities here should focus on the MMCAP cooperative purchasing model and generic pharmaceutical supply chains rather than clofexamide as a standalone commodity.